A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

NCT06259981 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: GLY-200
DRUG: Placebo

Sponsor

Glyscend, Inc.